Engineered Immune Therapy Eliminates Pediatric Brain Tumors in Preclinical Models
A new targeted immune therapy has successfully eliminated aggressive pediatric brain tumors in mice, with human clinical trials expected to begin in early…

Researchers have developed a novel CAR-T cell therapy, designated B-SYNC, capable of targeting and eliminating diffuse midline glioma (DMG) in mouse models. DMG is a highly aggressive pediatric brain cancer characterized by its location in the brainstem, which typically results in mortality within one year of diagnosis. Current standard-of-care treatments have demonstrated limited efficacy in halting disease progression.
The B-SYNC therapy utilizes a molecular switch mechanism that remains inactive while circulating in the bloodstream, thereby minimizing systemic toxicity. The immune cells are engineered to activate only upon detecting brevican, a protein abundantly expressed within the brain environment. Once activated, the cells target specific tumor-associated proteins, EphA2 and IL13Rα2, to destroy malignant tissue. Experimental data indicates that the therapy not only eradicated existing tumors but also provided sustained surveillance, preventing the recurrence of tumors when cancer cells were reintroduced.
The research team is currently preparing for clinical
This approach addresses a significant limitation in conventional CAR-T therapies, which often struggle to distinguish between tumor cells and healthy tissue, or fail to maintain efficacy due to tumor mutation and antigen loss. By utilizing a brain-specific protein as an activation signal rather than a tumor-specific mutation, the therapy may be applicable to a broader patient population. The research team is currently preparing for clinical trials, with initial human testing projected to commence as early as April 2027.
Institutional stakeholders should monitor the transition from murine models to human clinical trials, as the safety profile and efficacy of the B-SYNC mechanism in a complex human biological environment remain to be validated. The success of this trial could represent a significant shift in the treatment landscape for aggressive neurological malignancies, potentially impacting long-term oncology research investments and pediatric care protocols.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Adults 50 to 64 reach 7.5% heavy-drinking rate
- Dinch exposure correlates with 27-gram lower birth weight
- Three weekly wall-squat sessions cut systolic blood pressure 13.73 mmHg in small trial
- Jared Feather says knee fracture reshaped training for 18 months
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

